Introduction
Lennox-Gastaut syndrome (LGS) is a severe form of chronic epileptic encephalopathy that usually manifests in early childhood, with peak age of onset between 3 and 5 years [1] . The most common seizure types associated with LGS are tonic and atonic seizures, also known as "drop attacks," which occur in at least 50% of patients with LGS. Drop attacks are often the first seizure type to manifest in LGS and have the most potential for bodily harm [2, 3] . As a chronic syndrome, LGS requires lifelong treatment, and patients almost always develop progressive behavioral and psychological deficits [1, 3] . The treatment goal for most seizure disorders is complete seizure remission. However, remission is rarely achieved in LGS. Instead, the treatment goal for LGS is to improve individual patient quality of life through a decrease in seizure frequency with the fewest adverse events [4, 5] . The several seizure types experienced by patients with LGS (i.e., tonic, clonic, atypical absence, atonic, myoclonic, partial [focal] , generalized tonic-clonic, and nonconvulsive status epilepticus seizures) and their resistant nature often result in years of polytherapy [1, 4, 5] . The chronic, progressive, and complex nature of this syndrome makes LGS inherently difficult to treat, and a paucity of quality long-term trial data has also been an impediment to optimizing treatment for these patients [1, 4, 5] .
Clobazam is a novel 1,5-benzodiazepine approved by the US Food and Drug Administration (FDA) in October 2011 for the treatment of seizures associated with LGS. Clobazam, first approved in Australia in 1970 and in France in 1974 [6] , is also approved for the treatment of anxiety and many forms of epilepsy outside the United States. The US Food and Drug Administration's approval of clobazam for LGS was based on 2 randomized controlled trials, OV-1002 [7] and OV-1012 (also known as the CONTAIN trial) [8] . The OV-1002 study was a Phase II trial of patients with LGS 2-30 years of age, from which clobazam was found to be well-tolerated and to have decreased the weekly frequency of drop and non-drop seizures. Two clobazam dosages were studied (1.0 mg/kg/day and 0.25 mg/kg/day): Both dosages were efficacious, and the 1.0 mg/kg/day dosage was found to be more efficacious than the 0.25 mg/kg/day dosage. OV-1012 (the CONTAIN study) was a Phase III placebo-controlled trial evaluating 3 clobazam dosages in adult and pediatric patients 2-60 years of age. In this study, treatment with clobazam 0.25, 0.5, or 1.0 mg/kg/day was well-tolerated and efficacious in the treatment of drop seizures for patients with LGS. Compared with placebo, clobazam significantly decreased average weekly rates of drop seizures (12.1%, 41.2%, 49.4%, and 68.3% for the placebo, 0.25, 0.5, and 1.0 mg/kg/day dosages, respectively) and total seizures (9.3%, 34.8%, 45.3%, and 65.3% for the placebo, 0.25, 0.5, and 1.0 mg/kg/day dosages, respectively) [8] .
After participation in studies OV-1002 or OV-1012, patients were eligible to enroll in a long-term, open-label extension trial, OV-1004. An interim data analysis of this ongoing trial was conducted, covering the period from December 28, 2005, through July 1, 2010, and these data were used in the FDA's review of clobazam for approval. Safety and efficacy data from this interim analysis are presented here.
Methods

Study design
Qualifying patients from 2 randomized controlled studies (OV-1002 [7] and OV-1012 [8] ) were given the option of continuing clobazam treatment in OV-1004, an ongoing, multicenter, open-label study of clobazam as adjunctive therapy in patients with LGS 2-60 years of age. Patients who met the following criteria were eligible to enroll in OV-1004: b14 days since last dose of study drug in previous study, no serious or adverse events probably or definitely related to clobazam (as deemed by investigators), and receipt of ≤3 concomitant antiepileptic drugs (AEDs). Only in OV-1002 were vagus nerve stimulation (VNS) and ketogenic diet recorded as an AED when patients enrolled in the study. To account for this difference in methodology between OV-1002 and OV-1012, treatment baselines were adjusted for all OV-1012 patients so that the numbers of concomitant AEDs were calculated in the same manner as for OV-1002 patients. This is particularly important for the analysis reported in Section 3.3.2.4 covering changes over time in concomitant epilepsy treatments.
Receipt of > 3 concurrent AEDs was permitted after enrolment in OV-1004. The study designs for all 3 trials are provided in Fig. 1 .
When all required procedures from the previous blinded study were completed, patients were considered closed out of the previous blinded study and formally entered into the open-label study. The Day-1 procedures were performed, and open-label clobazam was dispensed to patients and/or their parents/caregivers. During the Day-1 visit, the patient or the patient's legally authorized representative signed and dated the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form/Health Insurance Portability and Accountability Act (HIPAA) authorization form and assent, if appropriate.
Patients who were undecided about continuing in the open-label study upon completion of the treatment period or premature discontinuation from OV-1002 or OV-1012 were considered eligible for enrollment for 14 days following their final doses of study drug. Patients who had decided to continue in the open-label study during this 14-day window returned to the investigational site for the Day-1 visit. If the investigator determined that there had been a significant change in a patient's medical history since the end of the previous blinded study, a complete physical examination and full neurologic examination were performed at the visit at Day 1 (versus using the information collected during the last visit of the previous blinded study) . During the open-label treatment period, patients returned to the investigational site at Week 1 (OV-1012 patients only) and Months 1, 2, 3, 6, 9, and 12, and then every 6 months thereafter. For patients outside the United States, the treatment period was limited to 24 months. Patients in the United States were allowed to remain in the trial until clobazam was commercially available. During the week preceding each study visit, the parent/caregiver, with the assistance of the patient, if able, maintained a seizure diary in which daily seizure counts (including drop seizures) were recorded. Patients who prematurely discontinued treatment or completed the study and did not continue on commercially available clobazam entered the 3-week taper period. The patients had a phone visit 2 weeks after entering the taper period and an office visit 1 week after the last dose of study drug.
Clobazam and concomitant AED dosing
Clobazam was given twice daily, in the morning and at bedtime. Patients from OV-1012 started at a target dosage of 0.5 mg/kg/day (maximum: 40 mg/day). This dosage was maintained for 48 h and then adjusted per clinical need. The unblinded physician adjusted or maintained the clobazam dosages the patients received in OV-1002 when they entered OV-1004. The maximum allowed daily dosage for all patients in OV-1004 was 2.0 mg/kg/day (maximum: 80 mg/day). While target dosages did not exceed 1.0 mg/kg/day (maximum: 40 mg/day) in the randomized Phase II and III clobazam studies [7, 8] , a target dosage of 2.0 mg/kg/day (80 mg/day) was allowed in the open-label extension study based on published reports of dosages >1 mg/kg/day (≤3.8 mg/kg/day, maximum 130 mg/day) being used in other refractory seizure disorders [9] .
To optimize patient care, investigators were able to start, adjust, and discontinue other AEDs and initiate other forms of treatment, including ketogenic diets and VNS placement. The primary efficacy outcome was the percentage decrease in the average weekly rate of drop seizures at various time intervals compared with baseline values (defined as the last 7 non-missing seizure entries; see "Statistical analyses," Section 2.5, for more details). The percentage decrease in the average weekly rate of total seizures was also measured. Drop seizures were recorded by patients' parents/ caregivers in daily seizure diaries. Drop seizure was defined as a drop attack or spell involving the entire body, trunk, or head that led to a fall, injury, slumping in a chair, or the patient's head hitting a surface, or that could have led to a fall or injury, depending on the patient's position at the time of the attack or spell. Drop seizures were recorded as a single seizure (occurring 15 min before and after the next seizure) or cluster of seizures (2 drop seizures with 5 min between any 2 consecutive seizures). For clusters, an exact number of drop seizures or a seizure range (10-20 drop seizures or >20 drop seizures) could have been recorded [8] .
Additional efficacy measures
Additional efficacy outcomes included time to discontinuation of clobazam, percentage of treatment responders, global evaluations of patients' overall changes in symptoms, and changes in concomitant AED use. Treatment responders were defined as patients with ≥ 25%, ≥50%, ≥75%, and 100% decreases in drop seizures or total seizures from the previous study baseline period. Investigator and parent/caregiver global evaluations of patients' overall changes in symptom assessments were based on a 7-point scale from 1 (very much improved) to 7 (very much worse), with lesser scores indicating improvement in overall evaluation of symptoms.
Safety assessments
The primary overall objective of the OV-1004 open-label trial was collection of safety information. The safety population included all patients who received ≥ 1 dose of clobazam during this trial. Measures included laboratory assessments (chemistry, hematology, and urinalysis), physical and neurologic examinations, vital sign monitoring, electrocardiogram monitoring, and adverse event reporting.
A serious adverse event was defined as any adverse event, which occurred at any dosage, that 1) resulted in death, 2) was life-threatening, 3) resulted in inpatient hospitalization or prolongation of existing hospitalization, 4) led to persistent or significant disability/incapacity, 5) yielded a congenital anomaly/birth defect, or 6) was an important medical event that, based on appropriate medical judgment, may have jeopardized a patient or required surgery or medical intervention to prevent the above outcomes. For an adverse event to be serious, it must have met one of these 5 predefined criteria. A severe adverse event was defined as any adverse event that may have interfered with the patient's usual activities and may have been incapacitating or life-threatening. Adverse events were deemed severe at the sole discretion of the individual study investigators.
Statistical analyses
The Safety Analysis Set consists of all patients who received ≥ 1 dose of clobazam in OV-1004. The Efficacy Analysis Set consists of all patients who received ≥1 dose of clobazam and had ≥ 1 efficacy measurement during the study. Selected variables are summarized for patients based on the timing of first dose compared with the date of the data cutoff in the trial. For example, a 6-month subset of patients received clobazam for at least 6 months but less than 12 months before data cutoff.
Demographic data for all patients were re-collected upon entry into OV-1004. Neurologic history data were only collected at screening in the previous blinded studies. Baseline values for seizure analyses were calculated as follows: (1) for patients who received placebo in OV-1012, baseline corresponded to the last 7 non-missing diary days; or (2) for patients who received clobazam in OV-1002 or OV-1012, baseline corresponded to the last 7 non-missing diary days from the baseline period of the blinded study. For all other parameters (e.g., exposure, laboratory evaluations, and vital signs), baseline was defined as the last value obtained before the first dose of clobazam, whether in the previous blinded study or OV-1004.
Efficacy analyses
This report includes all interim data as of July 1, 2010. All data are observed values and were summarized by study visit with descriptive statistics. Numbers and percentages were used for categorical variables, whereas mean, standard deviation (SD), median, minimum, and maximum values were used for continuous or ordinal measures. Calculation of values for clobazam treatment ≥ 1 day began on the day patients received their first doses of clobazam. For all clobazamtreated patients, the first dose of clobazam was received in OV-1002 and OV-1012, whereas placebo-treated patients from OV-1012 received their first doses of clobazam in OV-1004.
Safety analyses
For each patient, the most common (modal) and maximum dosages of clobazam were calculated. Descriptive summaries of the mean modal and mean maximum dosages were provided for patients who received clobazam for ≥1 day (any clobazam exposure), ≥6 months, and ≥12 months. In addition, the numbers and percentages of patients were cross-tabulated by modal dosage and days of clobazam exposure.
Treatment-emergent adverse events were summarized over time by severity (mild, moderate, or severe), relationship to treatment (not related, possible, or probable), and seriousness.
Results
Patient disposition
Enrollment in this open-label study began in December 2005 and ended in December 2009. This interim analysis reports data from the first patient enrolled to the most recent data cutoff, July 1, 2010.
A total of 267 patients enrolled in the open-label study and were included in the efficacy and safety populations for OV-1004 (Fig. 2) . As of the cutoff date for this interim analysis, 20% of patients had discontinued participation in the trial (Fig. 2) . The most common reason for discontinuation was patient, parent, or caregiver request (7.9%). Other reasons (b5%) included lack of efficacy, adverse events, and death. Treatment-emergent adverse events that led to premature discontinuation of clobazam were reported for 13 patients (4.9%). The only adverse events that led to premature discontinuation for >1 patient were pneumonia (3 patients) and death of unknown origin or etiology (2 patients). Time to discontinuation of clobazam ranged from 17 to 1317 days and is displayed graphically using KaplanMeier estimates in Fig. 3. 
Patient demographics
Demographics and baseline data from Day 1 in OV-1004 are presented in Table 1 . Mean age at the beginning of the trial was 11 years, with a mean time since LGS diagnosis of 4.3 years. All patients enrolled in the open-label extension trial were receiving concomitant AEDs at study entry. The most common concomitant AEDs received by patients at baseline were valproic acid (52%), lamotrigine (36%), levetiracetam (36%), and topiramate (30%). All concomitant AEDs received by > 10% of patients are presented in Table 1 .
Efficacy results
Primary efficacy outcome
The median percentage decreases from baseline in average weekly rate of drop seizures for total patients, regardless of duration of clobazam treatment, were 71.1% at Month 3 and 91.6% at Month 24 (Fig. 4) . Median percentage decreases in total seizures in this population were 64.8% at Month 3 and 81.5% at Month 24 (Fig. 4). 
Additional outcomes
3.3.2.1. Treatment responders. The percentage of patients with a ≥25%, ≥50%, ≥75%, or 100% decrease in average weekly seizure rate from previous blinded study baseline increased from Month 3 to Month 24 for both drop and total seizures (Figs. 5A and B) . The percentages of patients with a ≥ 50% drop seizure response rate were 61.5% at Month 3 (n = 252) and 79.5% at Month 24 (n = 88). The percentages of patients with a ≥ 50% total seizure response rate were 61.5% at Month 3 (n = 260) and 70.3% at Month 24 (n = 91).
Efficacy sustainment.
To determine if clobazam maintained a therapeutic effect in initial responders, we analyzed the percentages of patients over time who had ≥50%, ≥75%, or 100% decreases in average weekly rates of drop seizures for the subpopulation of patients who had attained ≥50% reduction at Month 3. Response to clobazam remained fairly consistent for those patients with initial responses, as measured by reduction in average weekly drop seizure rate (Table 2 ).
Physician and patient caregiver global evaluations.
The majority of patients were assessed by the physician as "very much improved" or "much improved" at all time points (range: 66.3-82.3%), and this percentage increased from Month 3 to Month 24 (data not shown). Similarly, the majority of patients were "very much improved" or "much improved" at all time points when assessed by the parent/ caregiver (range: 61.5-80.5%), and this percentage also increased from Month 3 to Month 24 (data not shown).
Concomitant epilepsy treatments.
Because of protocol deviations, differences in baseline inclusion criteria between the Phase II and III studies, and other reasons, 23 patients were receiving >3 concomitant epilepsy treatments at entry into OV-1004. Of these 23 patients who were receiving > 3 concomitant epilepsy treatments (AEDs, ketogenic diet, and/or VNS) at baseline, 10 (43.5%) were 3%) . A cross-tabulation of numbers of concomitant AEDs at baseline and final evaluation is provided in Table 3 .
Safety results
Extent of exposure
The mean modal and mean maximum dosages of clobazam were similar for patients with ≥ 1 day, ≥ 6 months, and ≥ 12 months of clobazam exposure (Table 4 ). The distribution of modal dosages did not change markedly for the group of patients who reached longer exposures to clobazam (≥ 24 months) compared with those who were in the study for short durations (data not shown). As of July 1, 2010, one patient received greater than the maximum per protocol dosage of clobazam (80 mg/day). This patient received a total clobazam dosage of 100 mg/day from October 26, 2009, to November 04, 2009. The weight of this patient during this period was 20.8 kg.
Adverse events
3.4.2.1. Incidence of adverse events. A total of 219 (82.0%) patients experienced ≥1 treatment-emergent adverse event during the openlabel study, and 140 (52.4%) patients experienced ≥1 adverse event that was treatment-related (defined as possible, probable, or definite relationship to study drug as assessed by the investigator). The most common treatment-emergent adverse events (≥10% of patients) in this extension study, in order of descending incidence, were upper respiratory tract infection (49/267, 18.4%), fall (38/267, 14.2%), pneumonia (37/ 267, 13.9%), somnolence (34/267, 12.7%), otitis media (32/267, 12.0%), pyrexia (28/267, 10.5%), and constipation (27/267, 10.1%). The upper respiratory tract infection and pneumonia events occurred predominantly in pediatric patients (80-90% in patients under the age of 18).
Of adverse events with an incidence ≥10% in OV-1004, the incidence and prevalence generally decreased after the first 6 months of treatment for the following: upper respiratory tract infection, somnolence, otitis media, and pyrexia.
Severity of adverse events.
Mild or moderate adverse events were reported for 160 patients (59.9%), and severe adverse events were reported for 59 patients (22.1%). Severe treatment-emergent adverse events reported for ≥1.0% of patients were pneumonia and convulsion (4.1% each), status epilepticus and pneumonia aspiration (1.5% each), and lobar pneumonia, sepsis, septic shock, urinary tract infection, dehydration, sedation, somnolence, and aggression (1.1% each).
3.4.2.3. Serious adverse events. Serious adverse events were reported for 85 patients (31.8%) during clobazam exposure in the OV-1004. Serious adverse events that occurred in more than 2% of patients were pneumonia (9.4%), convulsion (8.2%), pneumonia aspiration (3.7%), lobar pneumonia (2.2%), and urinary tract infection (2.2%). Treatment-related serious adverse events were reported for 15 patients (5.6%), of which pneumonia (4 patients), convulsion (3 patients), and status epilepticus (2 patients) were the only serious adverse events reported for > 1 patient.
As of the interim data cutoff (July 1, 2010), 6 patients (2.2%) had died during this open-label study. Fatal adverse events were pneumonia (2 patients); epilepsy (1 patient); pneumonia, sepsis, and acute respiratory distress syndrome (1 patient); and death of unknown origin or etiology (2 patients). None was considered related to clobazam treatment.
Discussion
This long-term study of clobazam (OV-1004) is the largest openlabel extension trial in patients with LGS published to date, and this interim analysis provides long-term data on the safety, tolerability, and efficacy of clobazam in this population. Notable findings include a high patient retention rate, stable dosages, and continued substantial seizure improvements for patients treated ≥ 2 years.
The paucity of long-term trial data has been a challenge for formulating LGS treatment guidelines. Only 2 other long-term extension trials have been presented, a 1-year extension of a felbamate trial with 73 patients [10] and a 3-year extension of a rufinamide trial with 124 patients [11] . The long-term data from OV-1004 should be valuable in helping physicians who treat patients with LGS determine long-term treatment options.
The intractable, variable, and progressive nature of LGS makes it one of the most challenging seizure disorders to diagnose and treat [1, 4] . In previous randomized trials, clobazam was found to be both safe and efficacious for treatment of seizures associated with LGS [7, 8] . Decreases in average weekly drop attacks and total seizures observed in the previous trials have been sustained and have continued to improve throughout the entire open-label trial to date. Responder rates, as measured by percentage decreases in weekly rate of drop attacks and total seizures, were also sustained through the first 2 years of this open-label extension trial, despite the fact that several confounding factors (e.g., other therapies, changes in disease course, varying treatment lengths at time of interim analysis, changes in clobazam dosage, and development of tolerance) may have affected response rates over time.
Given the variety of seizure types associated with LGS, drugs with a wide spectrum of efficacy are needed to treat this syndrome [5] . Although the goal of a broad-spectrum antiepileptic drug is to limit or at least delay the need for polytherapy [5] , it is likely, given the resistant nature of LGS and its heterogeneity, that more than one AED will eventually be needed for the vast majority of patients [1, 4] . Given the likely need for polytherapy for patients with LGS, the stability of the clobazam dosage was carefully monitored in the OV-1004 open-label extension trial and was generally stable and remained well less than 2 mg/kg maximum for most patients at the interim cutoff. Development of tolerance can often be a problem with 1,4-benzodiazepines [13] . Although we did not prospectively evaluate it per se, development of tolerance did not appear to be a significant factor, as suggested by the following: 1) No diminution of response rates was observed during the first 2 years of the open-label trial; 2) Mean modal clobazam dosages did not increase with time; 3) Approximately 80% of patients had remained in long-term treatment; and 4) A trend toward decreases in the numbers of concomitant epilepsy treatments was observed for some patients. Persistence of clobazam's efficacy was observed previously [9, 12] . Though efficacy data from long-term trials are informative, they should be interpreted with caution, as patients who discontinue because of a lack of efficacy may enrich the pool of patients for whom the drug is efficacious. At the data cutoff date, b 5% of patients discontinued the trial for lack of efficacy, indicating this is not yet a major factor in OV-1004. A common limitation of open-label extension studies is that patients who are the best responders tend to remain in the studies the longest, leading to responder bias. This bias may have occurred in our study as well, and its potential contribution to the results cannot be excluded. Further, OV-1004 study investigators were permitted to optimize treatment regimens for patients by freely adding, removing, or adjusting dosages of concomitant AEDs and employ other treatment options, such as VNS and ketogenic diet. In addition, the natural course of LGS varies considerably, and the disease may be less severe for older patients. Concomitant therapies, responder bias, and the variable natural course of the disease are potential confounders of the results presented here.
Unlike guidelines for most seizure disorders, complete seizure remission is not considered a realistic treatment goal in the consensus publication for LGS management, as it is rarely attained in patients with LGS [1] . Instead, overall patient quality of life is considered more important, and global evaluations by both the physician and caregiver/patient in this trial indicate that the majority of patients improved with clobazam treatment. The 80% retention rate in the first 2 years of OV-1004 also indicates overall treatment satisfaction and therapy compliance for most patients.
Since LGS is a syndrome that will require a lifetime of treatment and, likely, polytherapy, it is particularly important that drugs used in its management have a favorable long-term safety profile. Some of the approved treatments can have serious adverse effects, such as aplastic anemia (felbamate) [14, 15] and serious rash (lamotrigine) [16] . Clobazam seems to be well-tolerated, given the safety profile noted in this 2-year analysis. The most common adverse events reported with clobazam use, such as respiratory infections and falls, were to be expected in a long-term trial in the LGS patient population. In addition, upper respiratory tract infection and pneumonia events occurred predominantly in pediatric patients, which is quite common for trials in epilepsy with pediatric patients. The interim OV-1004 open-label extension trial data indicate no new safety concerns when compared with the results of short-term controlled trials.
The seemingly stable clobazam safety profile and potential for clinical benefit over the first 2 years of OV-1004, coupled with the decades of global use in LGS and other seizure disorders, indicate that clobazam is a viable long-term treatment option for this intractable epilepsy syndrome.
